Intercept Pharmaceuticals | ICPT - Pre Tax Profit


Intercept Pharmaceuticals reported $-5.83M in Pre-Tax Profit for its fiscal quarter ending in June of 2023.



Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -852K 7.26M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Esperion Therapeutics USD 63.67M 95M Dec/2025
Galectin Therapeutics USD -12.37M 880K Jun/2024
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Incyte USD 389.94M 92.37M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025